Highlights of ESH-iCMLf 28th Annual John Goldman Conference on CML

iCMLf Conversations on Chronic Myeloid Leukemia

Hear from Professor Daniela Krause and Professor Jorge Cortes about highlights from the 2025 ESH-iCMLf 28th Annual John Goldman Conference on CML

Biological overview

Expert

Professor Daniela Krause
Director of the Institute of Transfusion Medicine at the University of Mainz  (Germany)

Program

Overview of significant biological aspects presented during the conference, including:

  • Stem cells, clonal hematopoiesis and genetic mutations
  • Metabolism and immune mechanisms in CML
  • Blast crisis and disease progression
  • Bone marrow microenvironment
  • Minimal residual disease and treatment-free remission
  • Novel therapies and predictive markers
  • Emerging research: Glycobiology and cell death mechanisms
  • Special lectures: Pediatric CML, TKI resistance and transplantation

Clinical Overview

Expert

Professor Jorge Cortes
Georgia Cancer Centre, Augusta (USA)

Program

Overview of significant clinical aspects presented during the conference, including:

  • Predictors of treatment-free remission
  • ASC4START: Asciminib versus nilotinib
  • Advances in minimal residual disease monitoring
  • Genetic abnormalities and disease progression
  • Treatment-free remission: Benefits and challenges
  • Novel therapies: ELVN-001, ASC4OPT (Asciminib dosing strategies) and TGRX678
  • Advances in pediatric CML
  • New TFR strategies: NAUT (2 nd and subsequent TFR attempts) and HALF (stepwise
    dose reduction before discontinuation) studies
  • Advancing CML care in Ethiopia – iCMLf Prize 2026